AI Wins the COVID Race

Moderna arguably bested competitors Pfizer, Johnson and Johnson and AstraZeneca in the race to develop a safe-effective SARS-CoV-2 (COVID 19) vaccine.

Moderna was able to begin and complete clinical trials well ahead of it's competitors. https://www.zs.com/insights/understanding-covid19-vaccine-development-timelines

Unlike Pfizer's vaccine, Moderna's appears likely to sustain protection without potentially requiring a third dose. https://www.cnbc.com/2021/04/15/pfizer-ceo-says-third-covid-vaccine-dose-likely-needed-within-12-months.html

Unlike AstraZeneca's and Johnson and Johnson's vaccines, Moderna's has not been associated with risk of blood clots. https://www.nytimes.com/2021/04/10/health/astrazeneca-vaccine-blood-clots.html, https://www.bbc.com/news/world-us-canada-56733715

Moderna partnered with IBM to leverage AI and accomplish this industry leading achievement. https://www.fool.com/investing/2021/03/10/meet-modernas-surprising-new-covid-vaccine-partner/

As AI capabilities expand in scope and adoption, we can optimistically anticipate an increasingly efficient therapeutic development process, where the private sector rushes adoption of these new technologies in order to remain competitive and the public sector benefits from their thoughtful implementation.